HC Wainwright Issues Optimistic Forecast for ACRS Earnings

Key Points

• HC Wainwright raised its FY2026 EPS estimate for Aclaris Therapeutics to a loss of $0.61 per share from $0.62 and maintained a Buy rating with a $16 price target.
• Aclaris reported a narrower-than-expected quarterly loss of $0.15 per share and revenue of $1.63 million, exceeding the $1.38 million consensus estimate.
• Analyst sentiment remains broadly positive, with a consensus Buy rating and $11 price target, while institutional investors own 98.34% of the company’s shares.

Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) - Analysts at HC Wainwright increased their FY2026 earnings per share (EPS) estimates for Aclaris Therapeutics in a report released on Wednesday, October 28th. HC Wainwright analyst R. Selvaraju now forecasts that the biotechnology company will earn ($0.61) per share for the year, up from their prior forecast of ($0.62). HC Wainwright has a "Buy" rating and a $16.00 price target on the stock. The consensus estimate for Aclaris Therapeutics' current full-year earnings is ($0.62) per share. HC Wainwright also issued estimates for Aclaris Therapeutics' Q1 2027 earnings at ($0.13) EPS, Q2 2027 earnings at ($0.12) EPS, Q3 2027 earnings at ($0.14) EPS, Q4 2027 earnings at ($0.16) EPS and FY2027 earnings at ($0.55) EPS.

ACRS has been the subject of a number of other research reports. Weiss Ratings reiterated a "sell (d-)" rating on shares of Aclaris Therapeutics in a report on Monday, September 21st. Canaccord Genuity Group started coverage on shares of Aclaris Therapeutics in a report on Tuesday, September 1st. They set a "buy" rating and a $10.00 price objective on the stock. Wedbush lowered their target price on shares of Aclaris Therapeutics from $10.00 to $8.00 and set an "outperform" rating on the stock in a research report on Wednesday. Craig Hallum set a $9.00 target price on shares of Aclaris Therapeutics in a report on Wednesday. Finally, Wall Street Zen upgraded shares of Aclaris Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, October 24th. Three investment analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Aclaris Therapeutics has a consensus rating of "Buy" and a consensus price target of $11.00.

Aclaris Therapeutics Stock Up 0.8%

NASDAQ:ACRS opened at $3.99 on Friday. Aclaris Therapeutics has a fifty-two week low of $2.10 and a fifty-two week high of $6.60. The stock has a market cap of $557.90 million, a PE ratio of -6.88 and a beta of 0.87. The firm's fifty day simple moving average is $4.93 and its 200-day simple moving average is $4.51.

Aclaris Therapeutics (NASDAQ:ACRS - Get Free Report) last released its earnings results on Thursday, August 6th. The biotechnology company reported ($0.15) EPS for the quarter, beating analysts' consensus estimates of ($0.16) by $0.01. The company had revenue of $1.63 million during the quarter, compared to the consensus estimate of $1.38 million. Aclaris Therapeutics had a negative return on equity of 61.65% and a negative net margin of 921.50%.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the business. BlackRock Inc. purchased a new stake in Aclaris Therapeutics during the 2nd quarter worth about $53,096,000. Rock Springs Capital Management LP lifted its holdings in Aclaris Therapeutics by 0.4% in the 1st quarter. Rock Springs Capital Management LP now owns 4,472,650 shares of the biotechnology company's stock valued at $16,772,000 after purchasing an additional 18,909 shares in the last quarter. Braidwell LP lifted its holdings in Aclaris Therapeutics by 26.1% in the 2nd quarter. Braidwell LP now owns 2,142,348 shares of the biotechnology company's stock valued at $11,333,000 after purchasing an additional 443,232 shares in the last quarter. Palo Alto Investors LP acquired a new stake in shares of Aclaris Therapeutics during the 2nd quarter worth about $8,535,045. Finally, Kalehua Capital Management LLC acquired a new stake in shares of Aclaris Therapeutics during the 1st quarter worth about $6,871,000. 98.34% of the stock is owned by hedge funds and other institutional investors.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc NASDAQ: ACRS is a clinical-stage biopharmaceutical company focused on developing therapies for immune-inflammatory diseases. The company's research programs are designed to address conditions in areas such as rheumatology, dermatology and other inflammatory disorders.

Aclaris' lead investigational product is zunsemetinib (ATI-450), an oral small-molecule therapy being evaluated for inflammatory diseases. The company has also developed additional investigational programs, including selective kinase inhibitors intended for potential use in dermatologic and immune-mediated conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.